No abstract

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by the meticulous exclusion of all other possible causes. Drug dechallenge produces measurable improvement in symptoms and imaging in the majority of patients, whereas corticosteroid therapy is indicated if symptoms are present or drug dechallenge is without an effect. Rechallenge is justified in a minority of patients, and is discouraged for diagnostic purposes only. Pneumotox^® (www.pneumotox.com) provides updated information on drug-induced respiratory disease.

they elastically scatter off nuclei [4,5]. In recent decades, significant advances have been made in the search for WIMPs in the GeV/c 2 -to TeV/c 2 -range that is natural for Supersymmetry [6][7][8]. However, in the light of the absence of signal in that region there is an increasing interest in DM particles in the GeV/c 2 and sub-GeV/c 2 mass range [9][10][11][12][13][14][15]. These searches require experimental thresholds as low as a few tens of eV, a performance that can be attained by cryogenic detectors [16,17]. A particular advantage of such detector technology is that the thermal signal is not affected by the strong quenching effects that tend to severely reduce the amplitude of ionization or scintillation signals at low energy. This paper describes the results obtained by the EDELWEISS collaboration with a 33.4-g Ge detector demonstrating that such a device equipped with a neutron-transmutation-doped Ge (Ge-NTD) sensor [18] can reach the sensitivity to probe the sub-GeV domain. As a proof of the relevance of this technology, it is used in

This paper reports on the development of a technology involving 100 Mo-enriched scintillating bolometers, compatible with the goals of CUPID, a proposed nextgeneration bolometric experiment to search for neutrinoless double-beta decay. Large mass (∼ 1 kg), high optical quality, radiopure 100 Mo-containing zinc and lithium molybdate crystals have been produced and used to develop high performance single detector modules based on 0.2-0.4 kg scintillating bolometers. In particular, the energy resolution of the lithium molybdate detectors near the Q-value of the doublebeta transition of 100 Mo (3034 keV) is 4-6 keV FWHM. The rejection of the α-induced dominant background above 2.6 MeV is better than 8σ . Less than 10 µBq/kg activity of 232 Th ( 228 Th) and 226 Ra in the crystals is ensured by boule recrystallization. The potential of 100 Mo-enriched scintillating bolometers to perform high sensitivity double-beta decay searches has been demonstrated with only 10 kg×d exposure: the two neutrino double-beta decay half-life of 100 Mo has been measured with the up-to-date highest accuracy as T 1/2 = [6.90 ± 0.15(stat.) ± 0.37(syst.)] × 10 18 years. Both crystallization and detector technologies favor lithium molybdate, which has been selected for the ongoing construction of the CUPID-0/Mo demonstrator, containing several kg of 100 Mo.

PRISM (Polarized Radiation Imaging and Spectroscopy Mission) was proposed to ESA in May 2013 as a large-class mission for investigating within the framework of the ESA Cosmic Vision program a set of important scientific questions that require high resolution, high sensitivity, full-sky observations of the sky emission at wavelengths ranging from millimeter-wave to the far-infrared. PRISM's main objective is to explore the distant universe, probing cosmic history from very early times until now as well as the structures, distribution of matter, and velocity flows throughout our Hubble volume. PRISM will survey the full sky in a large number of frequency bands in both intensity and polarization and will measure the absolute spectrum of sky emission more than three orders of magnitude better than COBE FIRAS. The data obtained will allow us to precisely measure the absolute sky brightness and polarization of all the components of the sky emission in the observed frequency range, separating the primordial and extragalactic components cleanly from the galactic and zodiacal light emissions. The aim of this Extended White Paper is to provide a more detailed overview of the highlights of the new science that will be made possible by PRISM, which include: (1) the ultimate galaxy cluster survey using the Sunyaev-Zeldovich (SZ) effect, detecting approximately 106 clusters extending to large redshift, including a characterization of the gas temperature of the brightest ones (through the relativistic corrections to the classic SZ template) as well as a peculiar velocity survey using the kinetic SZ effect that comprises our entire Hubble volume; (2) a detailed characterization of the properties and evolution of dusty galaxies, where the most of the star formation in the universe took place, the faintest population of which constitute the diffuse CIB (Cosmic Infrared Background); (3) a characterization of the B modes from primordial gravity waves generated during inflation and from gravitational lensing, as well as the ultimate search for primordial non-Gaussianity using CMB polarization, which is less contaminated by foregrounds on small scales than the temperature anisotropies; (4) a search for distortions from a perfect blackbody spectrum, which include some nearly certain signals and others that are more speculative but more informative; and (5) a study of the role of the magnetic field in star formation and its interaction with other components of the interstellar medium of our Galaxy. These are but a few of the highlights presented here along with a description of the proposed instrument.

No abstract

Early recognition, prompt intervention, and a conservative approach are important in managing the risk associated with noninfectious pneumonitis in association with everolimus. Clinical trial registered with www.clinicaltrials.gov (NCT 00410124).

No abstract